Paper Details

  1. Home
  2. Paper Details

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

Author: , CavassiniMatthias, CusiniAlexia, DecosterdLaurent-Arthur, FuxChristoph, GutmannChristine, GünthardHuldrych F, HirschelBernard, VernazzaPietro L, YerlySabine

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Monotherapy with ritonavir-boosted lopinavir was not recommended as a standard strategy for HIV maintenance, especially in patients with a low nadir CD4 cell count. Viral failure was observed in patients with a low nadir CD4 cell count, and further research is needed to understand the role of the central nervous system in monotherapy failure.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Long-term side-effects and cost of HIV treatment motivate the development of simplified maintenance. Monotherapy with ritonavir-boosted lopinavir (LPV/r-MT) is the most widely studied strategy. However, efficacy of LPV/r-MT in compartments remains to be shown. METHODS: Randomized contro...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0b013e32833db9a1

データ提供：米国国立医学図書館（NLM）

LPV/r Monotherapy: A Complex Landscape in HIV Treatment

The quest for simplified and effective HIV treatment continues to drive research efforts. This study delves into the potential of monotherapy with ritonavir-boosted lopinavir (LPV/r-MT) as a maintenance strategy for HIV-infected individuals. The study employed a randomized controlled trial to compare LPV/r-MT with continued combination therapy in patients with fully suppressed viral load. The research found that LPV/r-MT was not effective as a stand-alone therapy, particularly in patients with a low nadir CD4 cell count, highlighting the importance of a nuanced approach to HIV treatment.

LPV/r-MT: A Cautionary Tale in HIV Treatment

The study reveals that LPV/r-MT is not a suitable maintenance strategy for all HIV-infected individuals. The research found that patients with a nadir CD4 cell count below 200/microl were more likely to experience treatment failure with LPV/r-MT. This finding underscores the importance of considering individual patient characteristics and viral load dynamics when making treatment decisions.

Navigating the Labyrinth of HIV Treatment

The study underscores the complexity of HIV treatment and the importance of personalized care. While LPV/r-MT may be a viable option for some patients, it is not a universally applicable solution. Further research is needed to better understand the factors that contribute to treatment failure with LPV/r-MT, enabling clinicians to make more informed decisions about HIV treatment strategies.

Dr.Camel's Conclusion

Like a camel navigating a shifting desert landscape, HIV treatment strategies require careful consideration and personalized attention. This study highlights the limitations of LPV/r-MT as a stand-alone therapy, particularly in patients with a history of low CD4 cell counts. The research serves as a reminder that the path to effective HIV treatment requires a thorough understanding of individual patient needs and ongoing vigilance in monitoring treatment response.

Date :
  1. Date Completed 2011-03-25
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

20802298

DOI: Digital Object Identifier

10.1097/QAD.0b013e32833db9a1

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.